Drugs and Devices

FDA approves Liposorber Apheresis System for pediatric use

On Oct. 10, the U.S. Food and Drug Administration (FDA) approved Liposorber LA-15 System to treat pediatric patients with primary focal segmental glomerulosclerosis (FSGS) either before transplant, or after renal transplantation when there is recurrence of FSGS. Read more.


Related Articles:

Leave a Reply

You have to agree to the comment policy.

 

Shares